Myriad Genetics (NASDAQ:MYGN - Get Free Report) updated its FY 2024 earnings guidance on Sunday. The company provided earnings per share (EPS) guidance of 0.140-0.150 for the period, compared to the consensus estimate of 0.130. The company issued revenue guidance of $836.0 million-$838.0 million, compared to the consensus revenue estimate of $840.2 million.
Myriad Genetics Stock Down 1.0 %
Shares of NASDAQ:MYGN traded down $0.13 during midday trading on Friday, hitting $12.39. 932,807 shares of the stock were exchanged, compared to its average volume of 848,447. The business's fifty day simple moving average is $14.68 and its two-hundred day simple moving average is $21.85. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics has a 52-week low of $12.17 and a 52-week high of $29.30. The company has a market capitalization of $1.13 billion, a PE ratio of -9.53 and a beta of 1.89.
Analyst Ratings Changes
Several research firms have recently issued reports on MYGN. Leerink Partners downgraded Myriad Genetics from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. Piper Sandler decreased their target price on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating for the company in a research report on Monday, November 11th. Stephens reissued an "equal weight" rating and issued a $20.00 price target on shares of Myriad Genetics in a research report on Thursday. Bank of America decreased their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an "underperform" rating for the company in a report on Friday, December 13th. Finally, StockNews.com upgraded shares of Myriad Genetics from a "hold" rating to a "buy" rating in a report on Thursday, January 9th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Myriad Genetics has an average rating of "Hold" and a consensus price target of $23.92.
Check Out Our Latest Research Report on MYGN
Myriad Genetics Company Profile
(
Get Free Report)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Recommended Stories
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
